Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 6/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | ACACA | Q13085 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5348078 | 0.84 | MAOB (0.60) | MAOBMAOAACACACYP4F2CYP4A11 | |
| SCHEMBL3098645 | 0.83 | CHRNB4 (0.51) | GRIN1GRIN2BKDM1A | |
| SCHEMBL24460873 | 0.82 | GRIN1 (0.53) | GRIN1GRIN2BMAOBMAOACYP4F2 | |
| SCHEMBL13106490 | 0.80 | GPR119 (0.46) | GRIN1GRIN2BACACA | |
| SCHEMBL1809933 | 0.80 | CTSL (0.45) | GRIN1GRIN2B | |
| SCHEMBL13096959 | 0.78 | SLC6A2 (0.61) | MAOBSPHK2SPHK1KDM1A | |
| Hydrochloric Acid SCHEMBL3096005 | 0.76 | SLC6A2 (0.59) | MAOBSPHK2SPHK1KDM1A | |
| SCHEMBL11047683 | 0.75 | GRIN1 (0.50) | GRIN1GRIN2BMAOBMAOAKDM1A | |
| SCHEMBL13096984 | 0.75 | MAOB (0.50) | MAOBMAOAACACACYP4F2CYP4A11 | |
| SCHEMBL13096963 | 0.73 | ALDH1A1 (0.53) | MAOBACACASPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | GRIN1 3120/4885GRIN2B 3501/4885MAOB 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.